Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-29

Clinical Trial Update: A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

View source ↗

Summary

A completed clinical trial update analyzing characteristics of people taking empagliflozin for type 2 diabetes based on German registry data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2021-03-29